World Journal of Urology

, Volume 30, Issue 3, pp 361–365 | Cite as

Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy

  • Eduard García-CruzEmail author
  • Jorge Huguet
  • Marta Piqueras
  • Meritxell Pérez Márquez
  • Lluís Peri
  • Laura Izquierdo
  • Agustín Franco
  • Ricardo Álvarez-Vijande
  • María José Ribal
  • Antonio Alcaraz
Original Article



Relationship between prostate cancer (PCa) and testosterone (T) is controversial. Conflicting evidence has been published about T levels and development of PCa.


(1) To determine the relationship between hormone levels and the diagnosis of PCa. (2) To specifically focus on the relationship between PCa and T in men classified as biochemically hypogonadal.

Materials and methods

Prospective analysis of 1,000 transrectal ultrasound guided prostate biopsies (5 + 5 cores biopsies) between September 2007 and January 2010 in one center. Indication for prostate biopsy was suspicion of PCa on the basis of elevated prostate-specific antigen (PSA) and/or digital rectal examination (DRE). Serum testosterone and sex hormones binding globulin (SHBG) were determined in these patients. Of 557 men, the data were sufficient for further analysis. Age, body mass index (BMI), smoking/drinking habits, PSA, free PSA, PSA density, prostate volume, number of previous biopsies, DRE, and hormone levels were prospectively recorded.


No relationship was found between T and PCa (449 ± 167 ng/dL in PCa versus 437 ± 169 ng/dL in non-PCa). SHBG was significantly higher in patients with PCa (51 ± 27 ng/dL in PCa vs. 44 ± 18 ng/dL in non-PCa). In hypogonadal men, T levels correlated with the PCa (235 ± 95 ng/dL in men with PCa versus 270 ± 58 ng/dL in men without PCa, P = 0.004).


T levels were comparable in men with and without PCa, but SHBG levels were significantly higher in men with PCa. In men with low T, the men with PCa had a lower serum T levels and a lower prostate volume than the men without PCa.


Prostate cancer Prostate biopsy Testosterone Hypogonadism 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2010) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2010 Oct 28Google Scholar
  2. 2.
    Huggins C, Hodges CV (1941) Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297Google Scholar
  3. 3.
    Huggins C, Stevens RE (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43:705–714Google Scholar
  4. 4.
    Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55(2):310–320PubMedCrossRefGoogle Scholar
  5. 5.
    Gray A, Feldman HA, McKinlay JB, Longcope C (1991) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 73(5):1016–1025PubMedCrossRefGoogle Scholar
  6. 6.
    Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26(6):833–876. Epub 2005 May 18Google Scholar
  7. 7.
    Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47(1):52–58PubMedCrossRefGoogle Scholar
  8. 8.
    Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20(6):605–608PubMedCrossRefGoogle Scholar
  9. 9.
    Hoffman MA, DeWolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163(3):824–827PubMedCrossRefGoogle Scholar
  10. 10.
    Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T (2003) Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169(5):1670–1675PubMedCrossRefGoogle Scholar
  11. 11.
    Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM (2005) Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174(6):2178–2180PubMedCrossRefGoogle Scholar
  12. 12.
    Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, Porena M (2008) Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 80(2):134–140PubMedCrossRefGoogle Scholar
  13. 13.
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16):1118–1126Google Scholar
  14. 14.
    Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, Hakama M (2004) High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108(3):418–424Google Scholar
  15. 15.
    Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60(11):1451–1457PubMedCrossRefGoogle Scholar
  16. 16.
    Rhoden EL, Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350(5):482–492PubMedCrossRefGoogle Scholar
  17. 17.
    Morgentaler A, Rhoden EL (2006) Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68(6):1263–1267PubMedCrossRefGoogle Scholar
  18. 18.
    Morgentaler A (2007) Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 52(3):623–625PubMedCrossRefGoogle Scholar
  19. 19.
    Morgentaler A (2009) Rapidly shifting concepts regarding androgens and prostate cancer. Sci World J 9:685–690CrossRefGoogle Scholar
  20. 20.
    Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2009) Investigation, treatment, and monitoring of late- onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 55:121–130PubMedCrossRefGoogle Scholar
  21. 21.
    Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM (2010) Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int 105(4):481–484. Epub 2009 Aug 13Google Scholar
  22. 22.
    Roddam A, Allen NE, Appleby P, Key TJ (2010) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. JNCI J Natl Cancer Inst 100:170–183Google Scholar
  23. 23.
    Morgentaler A, Bruning CO, De Wolf WC (1996) Occult prostate cancer in men with low serum testosterone levels. JAMA 276(23):1904–1906PubMedCrossRefGoogle Scholar
  24. 24.
    Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41(6):834–845PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Eduard García-Cruz
    • 1
    Email author
  • Jorge Huguet
    • 1
  • Marta Piqueras
    • 1
  • Meritxell Pérez Márquez
    • 1
  • Lluís Peri
    • 1
  • Laura Izquierdo
    • 1
  • Agustín Franco
    • 1
  • Ricardo Álvarez-Vijande
    • 1
  • María José Ribal
    • 1
  • Antonio Alcaraz
    • 1
  1. 1.Department of UrologyHospital Clínic de BarcelonaBarcelonaSpain

Personalised recommendations